T. Rowe Price Associates
VTGN icon

T. Rowe Price Associates’s VistaGen Therapeutics VTGN Stock Holding History

T. Rowe Price Associates’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,132
Closed -$5K – 2953
2023
Q1 		$5K Hold
1,132
– – ﹤0.01% 2900
2022
Q4 		$3K Buy
1,132
+534
+89% +$2.01K ﹤0.01% 2922
2022
Q3 		$3K Sell
598
-2,380
-80% -$23.6K ﹤0.01% 2941
2022
Q2 		$79K Buy
2,978
+32
+1% +$1.13K ﹤0.01% 2805
2022
Q1 		$110K Buy
2,946
+134
+5% +$5.84K ﹤0.01% 2832
2021
Q4 		$165K Buy
2,812
+950
+51% +$61.8K ﹤0.01% 2800
2021
Q3 		$153K Sell
1,862
-30
-2% -$2.61K ﹤0.01% 2775
2021
Q2 		$179K Buy
1,892
+575
+44% +$42.6K ﹤0.01% 2755
2021
Q1 		$84K Buy
+1,317
New +$87.9K ﹤0.01% 2793

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates's VTGN Position: Q2 2023 in Review

T. Rowe Price Associates sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 1,132 shares — an estimated $5K sold.

T. Rowe Price Associates first reported a position in VTGN in Q1 2021 and held it in 9 quarters. The position peaked at $179K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • T. Rowe Price Associates reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,132 VistaGen Therapeutics shares in Q2 2023, an estimated $5K.
  • T. Rowe Price Associates first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 9 quarters.
  • T. Rowe Price Associates's VistaGen Therapeutics position peaked at $179K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.